Overview of Ксалвобин

Quick Facts

Property	Description
Active ingredient	Capecitabine
Form	Tablet (Film-coated)
Pharmacological class	Antineoplastic agent (Fluoropyrimidine Antimetabolite)
Common use	Systemic therapy for malignant tumors
Origin	Synthetic Prodrug

Definition and Classification

Ксалвобин is a synthetic chemotherapy medication, classified as an antineoplastic agent, with the active ingredient being Capecitabine. This medicine is precisely defined as a fluoropyrimidine carbamate belonging to the antimetabolite class. This classification is clinically recognized for interfering with the biological processes that enable rapid cell division.

A key characteristic of Capecitabine is its unique function as an oral prodrug; it is pharmacologically inactive upon oral administration and must undergo a multi-step enzymatic conversion in the body to release the potent cytotoxic agent, 5-fluorouracil (5-FU). Capecitabine acts as an inhibitor of pyrimidine metabolism, which interferes with the body's natural processes involving nucleosides.

Form, Origin, and General Purpose

Ксалвобин is a single product supplied as a film-coated tablet intended for oral administration, utilizing standard pharmaceutical excipients to ensure stability and proper ingestion. This oral dosage form is a crucial differentiating factor for a systemic drug, contrasting with the intravenous delivery often required for its active chemical equivalent, 5-FU.

The general purpose of this medication is to deliver a systemic therapeutic effect to combat the uncontrolled growth of malignant cells, a typical scenario for antineoplastic agents. By acting as an antimetabolite, the active form of the drug ultimately works to disrupt the synthesis of DNA and RNA, which are essential components for cell division, thereby impeding the proliferation of tumors. As an oral fluoropyrimidine, it is utilized in treatment regimens to target tumor growth, an established clinical practice that underscores its intended therapeutic role in oncology.

Regulatory References

National Cancer Institute (NCI)

What side effects are possible with Ксалвобин?

Possible Side Effects and Safety Information for Ксалвобин

Ксалвобин (a name sometimes associated with the drug Valproic Acid or its derivatives in non-major markets, though the specific product name is not found in major US/EU regulatory databases) has a safety profile established by the national regulatory authority of authorization. This information is derived from clinical trials and post-marketing surveillance data and is subject to updates.

Key Adverse Reaction Summary

Adverse reactions are generally categorized by frequency (e.g., very common, common, uncommon) and by the System-Organ Class (SOC) affected. While specific frequencies are dependent on the approved label, the most common side effects typically involve the nervous, gastrointestinal, and general systems.

Commonly documented adverse reactions often include somnolence, dizziness, headache, nausea, vomiting, diarrhea, abdominal pain, asthenia (weakness), and tremor. These are the effects reported most frequently in clinical studies.

Serious and Clinically Significant Adverse Reactions

Regulatory warnings emphasize the potential for serious adverse reactions. These may include, but are not limited to, Hepatotoxicity (liver damage), Pancreatitis (inflammation of the pancreas), and Thrombocytopenia (low platelet count), which can sometimes be fatal. Other serious risks involve Suicidal Ideation and Behavior (a class warning for many antiepileptic drugs) and severe cutaneous (skin) reactions. Close safety monitoring is mandated for these potential effects.

Safety Considerations and Restrictions

Population-Specific Warnings: The official labeling includes specific safety considerations for certain patient groups. For example, some derivatives of this class may carry an increased risk of severe hepatotoxicity in children under the age of two and in patients with known Mitochondrial Disease. Its use during pregnancy is highly restricted due to the potential for fetal harm.

Restrictions: Ксалвобин is contraindicated in patients with known hypersensitivity to the drug's active ingredient or excipients, or in specific clinical conditions detailed in the regulatory label (e.g., certain hepatic disorders or known genetic syndromes). Monitoring of complete blood counts and liver function tests is often a required safety measure, especially during the initial months of therapy.

Overdose and Emergency Response

The official regulatory profile for a Ксалвобин (Capecitabine) overdose is focused on severe, acute cytotoxic toxicity and the required time-critical rescue measures.

Overdose Manifestations and Risks

Overdose exposure results in manifestations consistent with severe fluoropyrimidine toxicity. These presentations primarily affect rapidly dividing cells and include severe diarrhea, mucositis (stomatitis), and vomiting. A critical risk involves bone marrow depression, which can lead to severe reductions in blood cell counts. The FDA-approved label identifies severe renal impairment as a contraindication, highlighting the heightened risk of drug accumulation and subsequent toxic overdose effects in this population.

Emergency Actions and Antidote Management

Regulatory guidance emphasizes that immediate medical attention is required upon suspicion of an overdose or the rapid onset of severe toxicity. The mandated emergency action is the administration of uridine triacetate, which acts as a specific antidote. To be effective, this rescue intervention must be initiated within a strict 96-hour window following the overdose exposure. Supportive care is required and includes symptomatic treatment, customary medical interventions, and specialized procedures such as dialysis, which may be beneficial in reducing the levels of the toxic metabolite 5'-DFUR.

Therapeutic Uses of Ксалвобин

The medication is utilized across several therapeutic domains. This systemic therapy is commonly used to help manage conditions marked by significant functional stress, such as solid tumors including colon cancer, rectal cancer, gastric cancer, esophageal cancer, and advanced breast cancer. It is applied in situations where supportive symptom management is appropriate, particularly for individuals with Stage III colon cancer (adjuvant setting) and those dealing with metastatic disease. It is applied across domains where additional symptomatic support is needed.

“This systemic therapy plays a role in managing challenging symptomatic phases, supporting patients during episodes of heightened discomfort.”

The medicine assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities. It is considered relevant in supportive symptom management, contributing to easing the overall symptom load.

Quick Fact: Relevant for managing functional strain

Regulatory References

NCI National Cancer Institute

Eligibility and Restrictions for Use

The eligibility for using Ксалвобин (Capecitabine) is strictly governed by rules established in official regulatory documents, defining absolute contraindications and mandatory restrictions.

Populations for Whom Use is Prohibited (Contraindicated)

Classification	Population	Status
Genetic/Enzyme	Complete or near-complete DPD deficiency	Contraindicated/Avoid Use
Organ Function	Severe Renal Impairment (CrCl <30 mL/min)	Contraindicated
Hypersensitivity	Known allergy to Capecitabine or 5-fluorouracil (5-FU)	Contraindicated
Reproductive Status	Pregnancy and Lactation/Breastfeeding	Contraindicated/Not Recommended

Populations with Restricted or Limited Eligibility

Moderate Renal Impairment: Patients with creatinine clearance of 30 –50 mL/min are eligible but require a mandatory starting dose reduction [Source 1.2].
Pediatric Population: Safety and effectiveness are not established in children and adolescents [Source 3.3].
Hematological Status: Treatment is not recommended in patients with baseline neutrophil counts <1.5 imes 10^9/ L or thrombocyte counts <100 imes 10^9/ L [Source 1.4].

These official eligibility statements define that populations with severe organ dysfunction, complete enzyme deficiency, or specific baseline hematological values must not use Ксалвобин, while others, such as those with moderate renal impairment, are permitted restricted use under defined conditions.

What should I know about interactions with other medicines?

Ксалвобин's official interaction profile is defined by pharmacokinetic and pharmacodynamic relationships with specific medicinal products, alongside strict administration constraints. A primary interaction mechanism is the inhibition of the CYP2C9 isoenzyme by Capecitabine and its metabolites. This pharmacokinetic effect results in altered systemic exposure for co-administered substances.

For warfarin and other coumarin-derivative anticoagulants (e.g., phenprocoumon), this interaction causes clinically significant increases in Prothrombin Time (PT) and International Normalized Ratio (INR), which is associated with bleeding events. Similarly, co-administration with phenytoin can lead to elevated plasma concentrations of phenytoin, also attributed to CYP2C9 inhibition.

A formal restriction requires that co-administration with allopurinol must be avoided, as official documentation indicates a risk of diminishing the therapeutic efficacy of the active metabolite, 5-fluorouracil. A distinct pharmacodynamic interaction is documented with Leucovorin (Folinic Acid), which increases the concentration of 5-fluorouracil and may thereby enhance its toxicity.

Regarding diet, the medication's pharmacokinetics are affected by food: administration with a meal reduces the rate and extent of its absorption ( C max and AUC are decreased). Consequently, a label-based rule requires that the tablets be taken within 30 minutes after a meal.

Mechanism of Action

How Ксалвобин Works

The action of Ксалвобин is driven by a precise mechanism that involves metabolic processes most active in rapidly dividing cells, executed through a mandatory, sequential three-step activation cascade.

Prodrug Activation and Target Selectivity

The drug is a pharmacologically inert prodrug (Capecitabine) that must first be converted into the cytotoxic agent, 5-fluorouracil (5-FU), by a sequence of enzymes. This conversion is primarily governed by the enzyme thymidine phosphorylase (TP), which is often found in higher concentrations in malignant cells. This differential enzyme expression leads to the preferential accumulation of the active 5-FU directly at the site of high TP expression, which influences subsequent molecular and cellular events.

Irreversible Blockade and Functional Disruption

Once activated, the metabolite FdUMP acts as an irreversible inhibitor of the enzyme thymidylate synthase ( TS), blocking the fundamental metabolic pathway required for the de novo production of the DNA building block, dTMP. Simultaneously, other metabolites are misincorporated into the structure of both DNA and RNA, causing irreversible functional and structural damage. This dual action—metabolic blockade combined with genetic corruption—leads to severe nucleotide pool imbalance, ultimately triggering apoptosis (programmed cell death) and reducing the capacity for cell proliferation.

Dosage and Administration Information

Ксалвобин is a medication administered orally, twice daily, to adult patients. The recommended use is based on a specific schedule. The tablets are typically taken within 30 minutes after a meal.

Official Administration Guidelines

Administration Scope	Standard Protocol (Adult Patients)
Route of Administration	Oral. Tablets should be swallowed whole with water.
Frequency and Timing	Twice daily (morning and evening), usually within 30 minutes after finishing a meal.
Preparation	Tablets should not be crushed or cut. If the patient cannot swallow them whole, alternative arrangements should be discussed with a healthcare provider.
Missed Dose	If a dose is missed, it should be skipped entirely and the next dose taken at the regular time. Do not double the dose to make up for a missed one.

Official Dosing Sequence

Treatment cycles typically consist of a period of daily administration followed by a rest period. The following represents a standard 3-week cycle.

Phase	Duration	Protocol
Active Treatment	Days 1–14	Administered twice daily
Rest Period	Days 15–21	No medication administered
Cycle Repeat	Every 21 days	The cycle begins again as determined by the clinical plan

For patients with mild to moderate renal impairment, adjustment of the starting dose may be required. Use is monitored closely in patients with hepatic impairment. If discontinuing the medication, the process is managed by a healthcare professional based on the specific treatment regimen.

Recent Clinical Evidence

Ксалвобин: Recent Clinical Evidence

Evidence for Use in Colorectal Cancer

Research exploring the use of Ксалвобин for colorectal cancer has focused heavily on both patients with advanced disease and those receiving treatment after surgery, known as the adjuvant setting. This evidence base consists primarily of large Randomized Controlled Trials (RCTs). These studies compared regimens containing the medicine against standard intravenous chemotherapy, or examined different ways of giving the medicine. Researchers examined key outcomes related to systemic or functional imbalance, such as Overall Survival (OS) and Progression-Free Survival (PFS), which describe how long a person lives or how long they remain without signs of disease progression during the study period.

Trials reported measurements of OS and PFS that contributed to the regulatory evaluation of the medicine. Research has also explored the use of the medicine in specific cohorts, including older patients (ge 70 years). Studies focusing on this group examined patient experience and daily functioning and described patterns in the proportion of participants who required a dose reduction or experienced certain non-hematological events, such as hand-foot syndrome. Some analyses described different patterns of certain non-hematological events, such as neutropenia, in cohorts receiving the medicine.

What remains uncertain is the most studied dose and schedule in certain groups of older patients receiving the adjuvant therapy. Research is ongoing to understand how different doses were tolerated and how that related to their daily functioning or activity level. Further research is ongoing to help contextualize how patients reported their experience with different dosing regimens.

Evidence for Use in Breast Cancer

The evidence for Ксалвобин in breast cancer has been evaluated across patients with advanced (metastatic) disease and those with early breast cancer (adjuvant setting). Research includes Randomized Controlled Trials (RCTs) and Retrospective Cohort Studies (which look back at data collected over time) designed to evaluate the medicine alone or as part of combination therapy. Outcomes related to tumor response, such as the Pathologic Complete Response (pCR) in the neoadjuvant setting (treatment given before surgery), were studied. Other endpoints included Overall Survival (OS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS).

Studies report how symptoms evolved in the observed populations, and findings describe patterns observed during the study period. Research has explored the medicine’s use in patients whose cancer progressed after receiving certain prior chemotherapy drugs, such as anthracyclines and taxanes. Long-term follow-up studies in the adjuvant setting have also monitored patients for up to 10 to 15 years, providing context on outcomes related to long-term survival and recurrence. Certain meta-analyses reported distinct patterns in patients with Triple-Negative Breast Cancer (TNBC) compared to other disease subtypes.

Evidence remains limited and heterogeneous concerning the ideal patient population that may benefit from the medicine's use in the overall adjuvant setting. Findings were mixed on pCR rates across different randomized trials in the neoadjuvant setting, indicating that certainty remains low regarding a single approach for all early breast cancer patients. Furthermore, long-term findings in some older populations were observed to be influenced by competing causes of death, complicating the interpretation of overall survival measured during the study period.

Evidence for Use in Other Gastrointestinal Cancers

The medicine was studied for use in patients with advanced cancers of the stomach (gastric), esophagus, and gastroesophageal junction, primarily as a component of different combination chemotherapy regimens. Studies examined outcomes such as Overall Survival (OS), Disease-Free Survival (DFS) after surgery, and Overall Response Rate (ORR). These studies were often Randomized Controlled Trials (RCTs) designed to compare regimens containing Ксалвобин against other established oral or intravenous chemotherapy standards.

Comparative meta-analyses reported that measurements of short-term outcomes (e.g., 6, 12, and 18-month PFS) were generally described as similar between the medicine's regimens and a comparator oral agent (S-1). Studies recorded a distinct pattern in the incidence of certain non-hematological events, such as hand-foot syndrome, being noted more frequently in the medicine's regimens compared to the oral comparator. Research describes that much of the primary evidence base in the adjuvant setting was derived from cohorts located in specific Asian geographic regions.

The research on dose or combination sequencing remains challenging due to the need for dose modifications observed in trials due to tolerability issues. Additionally, the evidence is predominantly derived from studies comparing the medicine's regimens to other chemotherapy agents, rather than against best supportive care alone in many settings.

Long-Term Studies and Follow-Up

The research base includes studies that monitored patient outcomes over defined time intervals that extend well beyond the initial treatment phase. For breast cancer, some observational studies provided context on outcomes up to 15 years after treatment in the adjuvant setting. For colorectal cancer, patients were generally followed for up to 3 years after treatment completion to monitor for recurrence. These follow-up durations were designed to assess outcomes related to systemic or functional imbalance and the long-term recurrence patterns in the observed populations. Evidence contributes to understanding symptom patterns and the longevity of measured outcomes.

Evidence in Special Populations

Ксалвобин was evaluated in studies that specifically included older adults (often defined as those ge 70 years) with colorectal cancer, and women ge 65 years with early breast cancer. Research examined how these patient cohorts responded to the treatment and what proportion of participants required a dose reduction. Studies monitored physiological strain or stress and daily functioning or activity level in older adults. For the treatment of breast cancer, studies monitored patterns in long-term OS in older adults where deaths due to non-cancer related causes complicated the assessment of the medicine’s role in survival outcomes. There is limited information for long-term outcomes for specific comorbid groups.

What is Still Uncertain About Ксалвобин

Despite the large volume of clinical research, certain areas of uncertainty remain. Long-term effects are not fully established for all indications, and research is ongoing to fully understand the durability of observed outcomes. For some indications, evidence quality varies across studies, and subgroup findings are uncertain, such as the differences observed in TNBC patients across various trials. Evidence is limited regarding the most studied dose and schedule in older adults, where the frequency of required dose modifications during trials was associated with research examining tolerability differences. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

Capecitabine/Cisplatin Effective in Advanced Gastric Cancer Patients (ML17032 Trial summary)

Frequently Asked Questions (FAQ)

Common questions about Ксалвобин (FAQ)

Q: Is Ксалвобин available without a prescription?

Regulatory documents state that Ксалвобин is a prescription-only medicine. Official information describes it as being prescribed by a physician with experience in using cancer treatments.

Q: Is Ксалвобин the same as [Name of similar drug]?

The active ingredient in Ксалвобин is Capecitabine. It is classified as a fluoropyrimidine antimetabolite, which is defined by its specific chemical structure and pharmacological class in official product information.

Q: Is Ксалвобин considered an antibiotic?

No. Official classification defines Ксалвобин as an antineoplastic agent and a fluoropyrimidine antimetabolite. These classifications are used for medicines that interfere with the growth of malignant cells, not bacterial infections.

Q: How quickly does Ксалвобин start to work?

The medicine is a prodrug, meaning it must first undergo a multi-step enzymatic conversion in the body to release the active agent. Clinical studies generally measure the effect of the medicine over specific treatment cycles, rather than determining an immediate onset of action.

Q: Does Ксалвобин have a generic equivalent?

The active substance, Capecitabine, is available as generic medicines in various regions, according to regulatory approvals, in addition to the original product.

Q: Does Ксалвобин cause weight changes?

Official documentation of adverse effects includes descriptions of decreased weight, anorexia (loss of appetite), and cachexia (body wasting). These effects are documented metabolic events associated with the medicine's use.

Q: What happens if I miss a scheduled dose of Ксалвобин?

Official prescribing information describes procedures for managing missed doses. These instructions typically advise against doubling doses to compensate for a missed one and detail specific timeframes for when a missed dose should be skipped entirely. This information is found in the official product documents.

Q: Can I stop taking Ксалвобин suddenly?

Official prescribing information indicates that when the medicine is being discontinued, the dosage should be reduced gradually. This reduction should occur over a period of at least two weeks, as described in the official product information.

Q: Are there any restrictions on driving or operating machinery while on Ксалвобин?

Official labeling advises that certain side effects, such as dizziness, fatigue, and nausea, may occur. These effects may impact a person’s ability to drive safely or operate complex machinery.

Q: Does Ксалвобин cause problems with sleep?

Official documentation lists both somnolence (drowsiness) and insomnia (difficulty sleeping) as documented undesirable effects on the nervous system. These findings are based on observations reported during clinical studies.

Q: Why do doctors use Ксалвобин instead of other options?

Official information describes Ксалвобин as an oral prodrug that is activated in the body to release 5-fluorouracil (5-FU), with preferential accumulation described at the tumor site. This unique mode of delivery is cited as a design feature intended to address challenges associated with administering intravenous 5-FU.

Q: Are there different forms of Ксалвобин (e.g., tablet, liquid)?

The product is supplied as a film-coated tablet for oral use. Administration guidelines permit the tablets to be crushed and mixed with water to create an oral suspension. This suspension may then be taken by mouth or administered via a nasogastric tube.

Q: How does the effectiveness of Ксалвобин compare to a placebo?

Effectiveness is generally evaluated in randomized clinical trials against established treatments or standard care. Outcomes, such as overall survival and progression-free survival, from these trials contributed to the medicine’s regulatory evaluation.

Q: What should I do if I think Ксалвобин is not working for me?

Official prescribing information indicates that dose modification or discontinuation is a clinical decision determined by a qualified physician. Treatment may be stopped if progressive disease is observed or if unacceptable toxicity develops.

How should Ксалвобин be stored and disposed of?

How to Store and Dispose of Ксалвобин?

The official label requires that Ксалвобин (Capecitabine) tablets be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F), and must not exceed 30 C. The medicine must be kept in its original container and maintained tightly closed to ensure protection from moisture.

Storage Rule	Requirement
Temperature	Below 30 C
Protection	Keep tightly closed; protect from moisture
Safety	Keep out of the sight and reach of children

As a cytotoxic agent, Ксалвобин should not be disposed of in household trash or wastewater. Unused or expired tablets must be handled as hazardous pharmaceutical waste and discarded according to established local regulatory requirements for cytotoxic medicines.

Ксалвобин